Menu
Related Investments
Related Team

Arlington Capital Partners Announces Investment in Cambridge Major Laboratories, Inc.

WASHINGTON, DC, February 5, 2007 – Arlington Capital Partners, a Washington, DC-based private equity firm, today announced an investment in privately held Cambridge Major Laboratories, Inc. (www.c-mlabs.com) (“CML”), in partnership with the company’s existing management team. Headquartered in Germantown, WI, CML is a service-based chemistry outsourcing partner to the world’s leading pharmaceutical and biotechnology companies.

The Company operates two facilities outside of Milwaukee, WI offering synthesis and scale up, analytical chemistry services and associated regulatory support for active pharmaceutical ingredients (“APIs”) across a broad range of structural classes of molecules. Cambridge Major’s core services are targeted at a diversified customer base of pharmaceutical companies including large multinationals, generic manufacturers, emerging biotechnology companies and specialty pharmaceutical concerns.

“In the last several years, pharmaceutical companies have streamlined their internal operations and outsourced various drug functions, thereby converting previously fixed costs into variable costs” said Peter Manos of Arlington Capital Partners. “Outsourcing chemistry services allows pharmaceutical and biotechnology companies to use variable resources both tactically to maximize productivity during periods of rapid growth and strategically to add chemistry expertise that may not be needed on a fixed-cost basis.”

CML will continue to be led by its Chief Executive Officer, Michael Major, Ph.D., D.Sc., who, in conjunction with CML’s management team, has been responsible for the company’s growth since its founding in 1997. Michael Major is an industry leading expert in chemical synthesis and is currently the President of the Wisconsin Biotechnology and Medical Device Association. In addition, Dr. Major was recently named Entrepreneur of the Year in the category of Life Sciences by Ernst & Young.

Michael Major commented about the new relationship with Arlington: “We are excited to establish our partnership with Arlington and continue building Cambridge Major Laboratories into the industry leading contract chemistry services partner” said Major. “We have the unique opportunity to build on CML’s significant accomplishments with a partner that is committed to, and thoroughly understands, the outsourced pharmaceutical services industry. With the relationships, strategic focus and significant capital that Arlington brings, we look forward to continuing to exceed our customers’ expectations by accelerating our investment in facilities, personnel and equipment as well as expanding our breadth of service offerings.”

Matthew Altman of Arlington Capital Partners noted: “We were attracted to CML because of its leading position in the growing chemistry outsourcing marketplace and its outstanding management team. CML’s service offerings address its customers’ mission critical chemical synthesis needs and management’s commitment to product quality and on-time delivery distinguishes CML as a clear industry leader. CML is a premier platform in a compelling industry and we look forward to working closely with management to grow the business aggressively both organically and through acquisition.”

About Arlington Capital Partners

Arlington Capital Partners (www.arlingtoncap.com) is a Washington, DC-based private equity fund with over $1 billion of committed capital focused on middle market buyout investment opportunities in growth industries including: aerospace/defense, federal and commercial IT and engineering services, media, education & training, healthcare services and business services & outsourcing. The firm’s professionals have a unique combination of operating and private equity experience that enables Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company’s position as leading competitors in their field.

SOURCE: Arlington Capital Partners